BSX / Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21

Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter. more_horizontal

Boston Scientific (BSX) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to more_horizontal

Boston Scientific Corp. BSX, -1.90% posted better-than-expected third-quarter earnings early Thursday and raised its full-year guidance. The medical t more_horizontal

Medical device maker Boston Scientific topped Wall Street expectations for third-quarter profit on Thursday, helped by a resilient demand for its hear more_horizontal

Boston Scientific's quarterly results on Thursday are likely to show the benefits of a rebound in elective procedures and help ease fears that the med more_horizontal

With global staffing issues and the supply situation gradually improving, Boston Scientific's (BSX) international business is expected to have improve more_horizontal

One tool that investors can easily access for any stock is analyst ratings. These ratings point you in the direction of stocks to buy and stocks to se more_horizontal

Boston Scientific (BSX) receives the FDA's nod for an expanded indication of Wavewriter SCS Systems. more_horizontal